Eli Lilly (NYSE: LLY) sells treatments for a wide variety of therapeutic areas, but one portfolio in particular has driven ...

Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.

Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies ...

The Food and Drug Administration (FDA) said it will reconsider its decision to remove Eli Lilly’s blockbuster weight loss and ...

Britain will study whether the use of Eli Lilly's weight loss drug can get people back into work and help tackle the high ...

Eli Lilly (LLY) has partnered with the government of the United Kingdom to see if its blockbuster weight loss drug could help ...

The U.S. Food and Drug Administration on Friday agreed to reconsider a decision it made last month to bar drug compounders ...

Eli Lilly & Co plans to invest £279 million ($364 million) in a new initiative to support UK biotechs along with a study of ...

In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...

Eli Lilly (LLY) partners with British government for a first-of-its-kind real-world study on economic effects of its weight ...

The FDA said in a court filing late Friday that it would allow pharmacists to continue making compounded versions of ...

Britain is studying the use of Eli Lilly's weight loss drug, Tirzepatide, to address long-term sickness impacting its economy ...